Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutationTaehyang Lee(Sungkyunkwan University), Seung Tae Kim(Samsung Medical Center)Journal of CancerJanuary 1, 201810.7150/jca.26068Cited by 6SaveCiteExport RISWatch citationsRelated PapersTucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study|Journal of Clinical Oncology|2023|100The Impact of Cetuximab Plus AKT- or mTOR- Inhibitor in a Patient-Derived Colon Cancer Cell Model with Wild-Type RAS and PIK3CA Mutation|Journal of Cancer|2017|17